These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26298265)

  • 1. Cushing's syndrome with adrenal suppression and masked hyperandrogenism by high-dose medroxyprogesterone acetate for treatment of endometrial cancer in a young woman with polycystic ovarian syndrome.
    Seo Y; Jeong EG; Kim ES
    Endocrine; 2015 Nov; 50(2):519-21. PubMed ID: 26298265
    [No Abstract]   [Full Text] [Related]  

  • 2. Medroxyprogesterone acetate induced Cushing's syndrome.
    Shotliff K; Nussey SS
    Br J Clin Pharmacol; 1997 Sep; 44(3):304. PubMed ID: 9296330
    [No Abstract]   [Full Text] [Related]  

  • 3. Cushing's syndrome and hypothalamic-pituitary adrenal axis suppression induced by medroxyprogesterone acetate.
    Malik KJ; Wakelin K; Dean S; Cove DH; Wood PJ
    Ann Clin Biochem; 1996 May; 33 ( Pt 3)():187-9. PubMed ID: 8791979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progestogens and Cushing's syndrome.
    Harte C; Henry MT; Murphy KD; Mitchell TH
    Ir J Med Sci; 1995; 164(4):274-5. PubMed ID: 8522428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing's syndrome and adrenal insufficiency.
    Krueger RB; Hembree W; Hill M
    Sex Abuse; 2006 Apr; 18(2):227-8. PubMed ID: 16868842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of iatrogenic Cushing syndrome and apparent mineralocorticoid excess presenting with accelerated hypertension and proteinuria.
    Kong WY; Leedman P; Irish A
    Intern Med J; 2014 Sep; 44(9):932-4. PubMed ID: 25201428
    [No Abstract]   [Full Text] [Related]  

  • 7. [Conservative hormonal therapy for endometrial cancer].
    Susumu N; Aoki D; Tamada Y; Banno K; Suzuki A; Suzuki N; Nozawa S
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():375-80. PubMed ID: 15535271
    [No Abstract]   [Full Text] [Related]  

  • 8. Cushing's syndrome and medroxyprogesterone acetate.
    Grenfell A; Rudenski A; Watts M; Wiltshire C; Day JL; Gray IP
    Lancet; 1990 Jul; 336(8709):256. PubMed ID: 1973810
    [No Abstract]   [Full Text] [Related]  

  • 9. Conservative treatment of adenocarcinoma of the endometrium in young patients. Is it appropriate?
    Vinker S; Shani A; Open M; Fenig E; Dgani R
    Eur J Obstet Gynecol Reprod Biol; 1999 Mar; 83(1):63-5. PubMed ID: 10221612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cushing's syndrome induced by medroxyprogesterone.
    Merrin PK; Alexander WD
    BMJ; 1990 Aug; 301(6747):345. PubMed ID: 2144198
    [No Abstract]   [Full Text] [Related]  

  • 11. Cushing's syndrome in women with polycystic ovaries and hyperandrogenism.
    Fegan PG; Sandeman DD; Krone N; Bosman D; Wood PJ; Stewart PM; Hanley NA
    Nat Clin Pract Endocrinol Metab; 2007 Nov; 3(11):778-83. PubMed ID: 17955019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone therapy for uterine corpus cancer--introduction].
    Sugiyama T; Izutsu T
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():370-4. PubMed ID: 15535270
    [No Abstract]   [Full Text] [Related]  

  • 13. Differential diagnosis of hyperandrogenism in women with polycystic ovary syndrome.
    RachoĊ„ D
    Exp Clin Endocrinol Diabetes; 2012 Apr; 120(4):205-9. PubMed ID: 22421986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial carcinoma in a young patient with polycystic ovarian syndrome: first suspected at time of embryo transfer.
    Salha O; Martin-Hirsch P; Lane G; Sharma V
    Hum Reprod; 1997 May; 12(5):959-62. PubMed ID: 9194647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symptomatic Cushing's syndrome and hyperandrogenemia in a steroid cell ovarian neoplasm: a case report.
    Sedhom R; Hu S; Ohri A; Infantino D; Lubitz S
    J Med Case Rep; 2016 Oct; 10(1):278. PubMed ID: 27729065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allred score is a promising predictor of prognosis and medroxyprogesterone acetate efficacy in patients with endometrial cancer.
    Yunokawa M; Yoshida H; Watanabe R; Noguchi E; Shimomura A; Shimoi T; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):127-134. PubMed ID: 28540420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Megestrol-induced clinical adrenal insufficiency.
    Goodman A; Cagliero E
    Eur J Gynaecol Oncol; 2000; 21(2):117-8. PubMed ID: 10843465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.
    Thigpen JT; Brady MF; Alvarez RD; Adelson MD; Homesley HD; Manetta A; Soper JT; Given FT
    J Clin Oncol; 1999 Jun; 17(6):1736-44. PubMed ID: 10561210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized crossover study of medroxyprogesterone acetate and Diane-35 in adolescent girls with polycystic ovarian syndrome.
    Chung JP; Yiu AK; Chung TK; Chan SS
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):166-71. PubMed ID: 24656700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.